CORCEPT THERAPEUTICS I

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

11 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

03 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

29 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

06 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update

05 May 2022 16:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

28 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Appointment of Three Senior Leaders

07 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain

04 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

30 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022

01 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update

15 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

08 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer

20 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer

16 Dec 2021 08:00:02 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares

15 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

08 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock

08 Nov 2021 08:30:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update

03 Nov 2021 16:05:02 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

27 Oct 2021 16:05:01 By Nasdaq GlobeNewswire

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

17 Sep 2021 08:30:00 By Nasdaq GlobeNewswire